Primary outcome: Percentage change in body weight and the proportion of participants who lost at least 5% of baseline weight by week 68 Results: Primary outcome (% weight loss): Wegovy - 16%, Placebo - 5.7% (p 35 - 68.9% Randomized treatment groups Group 1 (374 patients): Tirzepatide titrated to the maximum tolerated dose of 10 mg or 15 mg once weekly Group 2 (376 patients): Semaglutide titrated to the maximum tolerated dose of 1.7 mg or 2.4 mg once weekly Tirzepatide was initiated at a dose of 2.5 mg once weekly, and the dose was increased by 2.5 mg every 4 weeks until a maximum tolerated dose of 10 mg or 15 mg was reached
Any unexpected reaction is reported through the clinics adverse-event protocol and triggers a documented response, not a generic chat reply
Efficacy 1.Anti-aging and reduce wrinkles (including: tightening the skin and improving the elasticity of the skin, improving the density and firmness of the skin, reducing fine lines and deep wrinkles, and improving the transparency of the skin) 2.Reduce photodamage and pigmentation of pigmentation 3.Significantly promote collagen synthesis and remodeling and regeneration of stromal dermal cells and keratinocytes 4.Reduce inflammation and redness 5.Promote hair growth Principle of action The blue copper peptide (GHK-Cu) is a tripeptide naturally occurring in the human body
By increasing GH and IGF-1 levels, it promotes lean body mass and aids in overall well-being, making it a potential therapy for age-related decline in muscle and cognitive health
Supporting Natural Healing Peptide therapy supports natural biological processes that already exist in the body
